Ip immunotherapy and chemotherapy in advanced epithelial ovarian cancer

E. Hernandez; N. B. Rosenshein; J. Pino y Torres; J. Villar; F. C. Grumbine; D. S. Ettinger; M. B. Dillon; J. L. Klein; S. E. Order

Ip immunotherapy and chemotherapy in advanced epithelial ovarian cancer

E. Hernandez, N. B. Rosenshein, J. Pino y Torres, J. Villar, F. C. Grumbine, D. S. Ettinger, M. B. Dillon, J. L. Klein, S. E. Order

School of Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Nine patients with advanced epithelial ovarian cancer, classified as either stage III with macrometastatic residual disease or stage IV, received combination chemotherapy in conjunction with ip rabbit-derived human ovarian antitumor serum (HOATS). The HOATS regimen consisted of the ip instillation of 100 ml of ovarian antitumor serum on Days 1 and 3 of the first chemotherapy cycle. Side effects attributable to HOATS were low-grade fever in three patients and diffuse skin rash in two. The 1-year cumulative survival was 87%, with a clinical response rate of 80%. No significant toxic-reactions of HOATS have been observed. Continuation of the present study seems justified.

Original language	English (US)
Pages (from-to)	1981-1982
Number of pages	2
Journal	Cancer treatment reports
Volume	66
Issue number	11
State	Published - 1982

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{0110e46ef67c4ebb8f4b6b3c31296350,

title = "Ip immunotherapy and chemotherapy in advanced epithelial ovarian cancer",

abstract = "Nine patients with advanced epithelial ovarian cancer, classified as either stage III with macrometastatic residual disease or stage IV, received combination chemotherapy in conjunction with ip rabbit-derived human ovarian antitumor serum (HOATS). The HOATS regimen consisted of the ip instillation of 100 ml of ovarian antitumor serum on Days 1 and 3 of the first chemotherapy cycle. Side effects attributable to HOATS were low-grade fever in three patients and diffuse skin rash in two. The 1-year cumulative survival was 87%, with a clinical response rate of 80%. No significant toxic-reactions of HOATS have been observed. Continuation of the present study seems justified.",

author = "E. Hernandez and Rosenshein, {N. B.} and {Pino y Torres}, J. and J. Villar and Grumbine, {F. C.} and Ettinger, {D. S.} and Dillon, {M. B.} and Klein, {J. L.} and Order, {S. E.}",

year = "1982",

language = "English (US)",

volume = "66",

pages = "1981--1982",

journal = "Cancer treatment reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Ip immunotherapy and chemotherapy in advanced epithelial ovarian cancer

AU - Hernandez, E.

AU - Rosenshein, N. B.

AU - Pino y Torres, J.

AU - Villar, J.

AU - Grumbine, F. C.

AU - Ettinger, D. S.

AU - Dillon, M. B.

AU - Klein, J. L.

AU - Order, S. E.

PY - 1982

Y1 - 1982

N2 - Nine patients with advanced epithelial ovarian cancer, classified as either stage III with macrometastatic residual disease or stage IV, received combination chemotherapy in conjunction with ip rabbit-derived human ovarian antitumor serum (HOATS). The HOATS regimen consisted of the ip instillation of 100 ml of ovarian antitumor serum on Days 1 and 3 of the first chemotherapy cycle. Side effects attributable to HOATS were low-grade fever in three patients and diffuse skin rash in two. The 1-year cumulative survival was 87%, with a clinical response rate of 80%. No significant toxic-reactions of HOATS have been observed. Continuation of the present study seems justified.

AB - Nine patients with advanced epithelial ovarian cancer, classified as either stage III with macrometastatic residual disease or stage IV, received combination chemotherapy in conjunction with ip rabbit-derived human ovarian antitumor serum (HOATS). The HOATS regimen consisted of the ip instillation of 100 ml of ovarian antitumor serum on Days 1 and 3 of the first chemotherapy cycle. Side effects attributable to HOATS were low-grade fever in three patients and diffuse skin rash in two. The 1-year cumulative survival was 87%, with a clinical response rate of 80%. No significant toxic-reactions of HOATS have been observed. Continuation of the present study seems justified.

UR - http://www.scopus.com/inward/record.url?scp=0020382048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020382048&partnerID=8YFLogxK

M3 - Article

C2 - 7139641

AN - SCOPUS:0020382048

SN - 0361-5960

VL - 66

SP - 1981

EP - 1982

JO - Cancer treatment reports

JF - Cancer treatment reports

IS - 11

ER -

Ip immunotherapy and chemotherapy in advanced epithelial ovarian cancer

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this